Psoriasis Support protocol

Psoriasis Support

skin conditionsmoderate evidence

About this protocol

Psoriasis is a chronic, immune-mediated inflammatory disease affecting 2-3% of adults. The hallmark is accelerated keratinocyte turnover — skin cells replicating every 3-5 days instead of the normal 28-30 — driven by a Th17/IL-23 immune axis. Clinically that shows up as well-demarcated red plaques with silvery scale, classically on the elbows, knees, scalp, and lower back. Psoriasis is not just a skin disease: it carries substantial comorbid risk. Roughly 30% of patients develop psoriatic arthritis, and the cohort as a whole runs higher cardiovascular disease, metabolic syndrome, and depression rates than the general population. Treatment is genuinely multi-modal — topical corticosteroids and vitamin D analogs (calcipotriol) for limited disease, phototherapy for wider involvement, and systemic biologics targeting IL-17 (secukinumab/Cosentyx), IL-23 (risankizumab/Skyrizi, guselkumab/Tremfya, ustekinumab/Stelara), or TNF-alpha (adalimumab/Humira) for moderate-to-severe disease. If you have moderate-to-severe psoriasis — significant body surface area, scalp/genital/palmar-plantar involvement, joint symptoms, or quality-of-life impact — see a dermatologist. The biologics era has been transformative; PASI 90 (90% lesion clearance) is now a realistic goal for most patients, not the exception. Supplements occupy a supportive role: they can blunt systemic inflammation, correct deficiencies that worsen disease activity, and address the cardiometabolic comorbidity burden. They don't replace appropriate dermatologic care for anything beyond mild localized disease.

Where to start

See a dermatologist first if your disease is more than mild and localized. Modern biologics have changed the calculus — if plaques cover more than a few percent of body surface area, involve the scalp/genitals/palms/soles, or you have joint symptoms, supplements are not the right primary intervention. Ask specifically about IL-17 and IL-23 blockers.

Start with vitamin D3 at 2000-4000 IU/day, dose adjusted to serum 25(OH)D. Psoriasis patients often run lower 25(OH)D than controls. Aim for serum 40-60 ng/mL. The same vitamin D pathway is targeted by prescription topical calcipotriol — oral D in deficient patients supports the same axis systemically.

Add omega-3 EPA-dominant at 2-3 g combined EPA+DHA daily. Meta-analytic evidence (Clark 2019) supports modest PASI score improvement at higher doses. Pair with a fat-containing meal.

Consider curcumin (phytosome) — the Meriva-formulation trial (Antiga 2015) showed adjuvant benefit on top of topical steroids, with reductions in IL-22 serum levels. Phytosome formulations meaningfully improve bioavailability over raw turmeric.

Consider vitamin B12 (methylcobalamin) if you're deficient or homocysteine is elevated. Topical B12 + avocado oil has small trial support; oral B12 has indirect cardiovascular rationale in this cohort.

Treat vitamin A as food-first, not high-dose. Prescription retinoids (acitretin, isotretinoin) are highly effective for psoriasis — but high-dose OTC vitamin A is dangerous (teratogenic, hepatotoxic). Get vitamin A from food (sweet potato, liver, leafy greens, eggs). If you supplement, stay at RDA (700-900 mcg RAE).

Re-evaluate at 12-16 weeks. If plaques are thinner, less itchy, and clearing — continue. If unchanged, the bottleneck is immunologic and a biologic conversation with your dermatologist is the highest-value next step.

5 nutrients

Start here

Strongest evidence — the foundation of the stack.

Vitamin D3 (Cholecalciferol)

2000-4000 IU daily; adjusted to maintain serum 25(OH)D at 40-60 ng/mL
morningwith food

The vitamin D pathway is mechanistically central to psoriasis — prescription topical vitamin D analogs (calcipotriol, calcitriol) are first-line for limited plaque disease, working through VDR-mediated modulation of keratinocyte differentiation and Th17 immunity. Psoriasis patients more commonly run low 25(OH)D than controls. The Formisano 2023 systematic review and meta-analysis found that oral vitamin D supplementation produced meaningful PASI improvements, with greater effect in deficient patients. Target serum 40-60 ng/mL; higher doses are appropriate when baseline is deficient. Pair with K2 if taking long-term and not eating vitamin K-rich foods.[1, 2, 3]

Omega-3 (EPA-dominant fish oil)

2-3 g combined EPA+DHA daily (EPA-dominant), with a fat-containing meal
morningwith food

Omega-3 EPA/DHA reduces pro-inflammatory eicosanoids (PGE2, leukotriene B4) and dampens the Th17/IL-17 axis implicated in psoriasis. The Clark 2019 meta-analysis of 10 RCTs (560 participants) demonstrated significant reduction in PASI score with omega-3 supplementation, with more pronounced benefits at higher doses (≥2 g/day combined EPA+DHA). Earlier Søyland 1993 NEJM dietary supplementation trial provided foundational evidence. The effect is real but modest — pair with appropriate topical or systemic therapy, not substitute. EPA-dominant formulations preferred for inflammatory endpoints.[3, 4, 5, 6]

Add if needed

Add these only if the foundation isn't enough.

Curcumin (Phytosome / Meriva)

1-2 g phytosome curcumin (e.g., Meriva) daily, divided with meals
morningwith food

Curcumin inhibits NF-kB signaling, a pathway upstream of multiple cytokines (TNF-alpha, IL-17, IL-22) implicated in psoriasis pathology. The Antiga 2015 randomized, double-blind, placebo-controlled trial in 63 patients with mild-to-moderate psoriasis vulgaris found that 2 g/day Meriva (a phytosome curcumin) added to topical steroids significantly improved PASI scores and reduced serum IL-22 compared with placebo plus topical steroids. Bioavailability is the bottleneck for plain turmeric; phytosome (lecithin-complexed) or piperine-paired formulations are meaningfully better absorbed. Best treated as adjuvant — not a replacement for established therapy.[7, 8]

Vitamin B12 (Methylcobalamin)

500-1000 mcg methylcobalamin daily (oral or sublingual)
morningempty stomach

Topical vitamin B12 (combined with avocado oil) has small randomized trial support for plaque psoriasis (Stücker 2001), and B12 deficiency is more common in psoriasis patients than controls. Oral B12 is most relevant when serum B12 is low or homocysteine is elevated — both of which are over-represented in psoriasis cohorts and contribute to the elevated cardiovascular risk profile. Methylcobalamin and adenosylcobalamin are the bioactive forms; cyanocobalamin requires conversion. Inexpensive, low-risk, and reasonable in this patient population even when the dermatologic effect is small.[3, 9, 10]

Experimental

Emerging evidence — try last, only if curious.

Vitamin A (food-first; RDA only if supplementing)

RDA only: 700 mcg RAE/day (women), 900 mcg RAE/day (men). PREFER FOOD SOURCES. Do NOT exceed RDA without medical supervision.
morningwith food

Prescription retinoids (oral acitretin, isotretinoin; topical tazarotene) are gold-standard therapeutic agents for psoriasis, working through retinoic acid receptor-mediated normalization of keratinocyte differentiation. This does NOT translate to high-dose OTC vitamin A being safe or effective — preformed vitamin A (retinol, retinyl esters) is fat-soluble, accumulates, and at supra-physiologic doses is teratogenic (severe birth defects) and hepatotoxic. The correct approach is food-first: sweet potato, liver, eggs, leafy greens, orange/yellow vegetables (beta-carotene precursor is non-toxic at dietary intakes). If you supplement, stay at the RDA. Prescription retinoid therapy belongs with your dermatologist, not your supplement stack.[3, 11, 12]

Warnings

Do not take with: Anticoagulants and antiplatelets (omega-3 at high doses may modestly increase bleeding risk; curcumin has antiplatelet activity at higher doses). Topical and oral retinoids — acitretin, isotretinoin, tazarotene — never stack supplemental vitamin A on top of prescription retinoid therapy (additive hypervitaminosis A risk, hepatotoxicity, teratogenicity). Methotrexate (curcumin may affect hepatic metabolism; discuss with your prescriber). Tetracycline antibiotics combined with vitamin A risk pseudotumor cerebri. Hepatotoxic medications generally — defer high-dose vitamin A or curcumin if on therapy that taxes the liver.
Do not take if: You are pregnant, breastfeeding, or planning pregnancy in the near term — preformed vitamin A above the RDA is teratogenic; prescription acitretin and isotretinoin are absolutely contraindicated and require effective contraception. You have active liver disease — defer curcumin and vitamin A supplementation. You have moderate-to-severe psoriasis that warrants biologic therapy — see a dermatologist; supplements are complementary, not a substitute for IL-17/IL-23/TNF blockade. You have erythrodermic or pustular psoriasis — these are dermatologic urgencies, not supplement-managed conditions. You have known psoriatic arthritis with joint damage — supplements do not prevent erosive disease; biologic therapy does.

Lifestyle improvements

Mediterranean diet pattern

The Mediterranean diet — olive oil, fish, nuts, legumes, vegetables, whole grains, modest wine — has the strongest dietary evidence base in psoriasis. Observational cohorts and small interventional trials show lower PASI scores and reduced disease activity in patients with higher adherence. The mechanism is plausibly anti-inflammatory: lower omega-6:omega-3 ratio, higher polyphenol intake, lower refined carbohydrate load. This is the single most evidence-backed dietary lever.

Reduce or eliminate alcohol

Alcohol is a documented psoriasis flare trigger and worsens treatment response. The mechanism includes direct dermal vasodilation, increased TNF-alpha production, immune dysregulation, and interaction with hepatotoxic systemic therapies (especially methotrexate and acitretin). Heavy alcohol use also independently raises cardiovascular risk — a major comorbidity in this population. Cutting back is high-value.

Stop smoking

Smoking is associated with psoriasis incidence, severity, and reduced response to therapy — particularly palmoplantar pustulosis. Nicotine alters keratinocyte function and neutrophil chemotaxis. Smoking cessation modestly improves disease activity and substantially reduces the cardiovascular comorbidity burden that psoriasis already amplifies.

Weight loss if overweight

Psoriasis severity correlates with body weight, and intentional weight loss (via Mediterranean diet, caloric restriction, or GLP-1 agonists) reproducibly reduces PASI scores and improves biologic response rates. Adipose tissue is a source of inflammatory cytokines that worsen psoriasis; reducing it removes that fuel. This is one of the few lifestyle changes with both skin and joint payoff.

Stress management

Stress is among the most consistently patient-reported flare triggers. Acute psychological stress demonstrably activates the HPA axis and skin neurogenic inflammation. Daily breathwork, mindfulness, regular sleep, and addressing depression (which is overrepresented in psoriasis cohorts) compound with the medical regimen. Don't treat the mental health dimension as secondary.

Screen for and manage cardiometabolic comorbidities

Moderate-to-severe psoriasis carries a documented elevation in cardiovascular risk, type 2 diabetes, metabolic syndrome, and non-alcoholic fatty liver disease. Annual blood pressure, fasting glucose/HbA1c, lipid panel, and BMI checks are appropriate. Statin therapy, antihypertensives, and metformin should be considered on standard cardiovascular criteria — and probably with a lower threshold given the inflammatory amplification.

Watch for joint symptoms — psoriatic arthritis

About 30% of psoriasis patients develop psoriatic arthritis, often years after skin disease onset. Morning stiffness, joint swelling, enthesitis (heel/Achilles pain), dactylitis ("sausage digits"), or back stiffness with inflammatory features warrant rheumatology referral. Joint damage is permanent; early biologic therapy prevents erosion. Don't dismiss new joint symptoms as unrelated.

Address depression and anxiety

Depression prevalence in moderate-to-severe psoriasis is roughly 2-3x the general population. The relationship is bidirectional: chronic visible disease drives mood symptoms, and depressive cytokine biology (elevated TNF-alpha, IL-6) worsens skin disease. Treatment of depression — therapy, SSRIs, or biologic clearance of skin disease that secondarily improves mood — should be considered an integral part of psoriasis care, not a separate problem.

Phototherapy where appropriate

Narrowband UVB phototherapy remains a highly effective, well-tolerated option for moderate psoriasis when topicals are insufficient and biologics are not yet warranted. Home units exist. Sensible sunlight exposure (short, regular, not burning) often helps. This is dermatologist-supervised territory — not "tan more."

Ask about biologics when topicals plateau

If you've maximized topical therapy and have persistent moderate-to-severe disease, ask your dermatologist about IL-17 (secukinumab, ixekizumab), IL-23 (risankizumab, guselkumab, ustekinumab), or TNF blockade (adalimumab, etanercept). PASI 90 is a realistic and common outcome with modern biologics — the goalpost has moved. Insurance coverage and patient-assistance programs make access more feasible than many patients assume.

References

  1. Vitamin D — supplement research overviewExamine.com link
  2. Formisano E, Proietti E, Borgarelli C, Pisciotta L. Psoriasis and Vitamin D: A Systematic Review and Meta-Analysis. Nutrients. 2023;15(15):3387.PubMed link
  3. Millsop JW, Bhatia BK, Debbaneh M, Koo J, Liao W. Diet and psoriasis, part III: role of nutritional supplements. J Am Acad Dermatol. 2014;71(3):561-569.PubMed link
  4. Fish oil — supplement research overviewExamine.com link
  5. Clark CCT, Taghizadeh M, Nahavandi M, Jafarnejad S. Efficacy of ω-3 supplementation in patients with psoriasis: a meta-analysis of randomized controlled trials. Clin Rheumatol. 2019;38(4):977-988.PubMed link
  6. Søyland E, Funk J, Rajka G, et al. Effect of dietary supplementation with very-long-chain n-3 fatty acids in patients with psoriasis. N Engl J Med. 1993;328(25):1812-1816.PubMed link
  7. Curcumin — supplement research overviewExamine.com link
  8. Antiga E, Bonciolini V, Volpi W, Del Bianco E, Caproni M. Oral Curcumin (Meriva) Is Effective as an Adjuvant Treatment and Is Able to Reduce IL-22 Serum Levels in Patients with Psoriasis Vulgaris. Biomed Res Int. 2015;2015:283634.PubMed link
  9. Vitamin B12 — supplement research overviewExamine.com link
  10. Stücker M, Memmel U, Hoffmann M, Hartung J, Altmeyer P. Vitamin B(12) cream containing avocado oil in the therapy of plaque psoriasis. Dermatology. 2001;203(2):141-147.PubMed link
  11. Vitamin A — supplement research overviewExamine.com link
  12. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072.PubMed link
  13. Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017;76(3):377-390.PubMed link

Track this protocol in Pilora

Add these supplements to your shelf, get smart dose reminders, and check for interactions — all in the Pilora iPhone app.

Coming to App Store

Disclaimer: These statements have not been evaluated by the FDA. This protocol is educational, not a substitute for personalized medical advice. Talk to your doctor before starting any new supplement regimen — especially if you're pregnant, breastfeeding, on medications, or managing a chronic condition. Last updated 5/20/2026.